DOUG CLARK Good afternoon and thank you for joining us. With me on the call today are Shantanu Narayen, Adobe's Chair and CEO, David Wadhwani, President of Digital Media, Anil Chakravarthy, President of Digital Experience, and Dan Durn, Executive Vice President and CFO. 1 On this call, which is being recorded, we will discuss Adobe's fourth quarter and fiscal year 2025 financial results. You can find our press release, as well as PDFs of our prepared remarks and financial results, on Adobe's Investor Relati ...

Corporate Overview for Investors December 2025 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding Synopsys, Inc.'s (Synopsys, we or our) short-term and long-term financial targets, expectations and objectives; our businesses, business segments, strategies, partnerships, initiatives and opportunities, including, among other things, the reallocation of resources in our Design IP segment to higher growth opportunities and planne ...

Financial Performance - Talent Development Solutions (TDS) revenue was $100.8 million, a decrease of $2.2 million or 2% year-over-year[23] - Global Knowledge (GK) revenue declined by 18% in Q3 FY2026[27] - Q3 FY2026 Adjusted EBITDA was $28.0 million, representing 22% of revenue, a decrease of approximately 160 basis points year-over-year[23] - Q3 FY2026 Free Cash Flow was negative $23.6 million[31] - Adjusted Operating Expenses were $101.0 million, a decrease of 4.1% year-over-year[32,41] Key Performance Indicators - Last Twelve Months (LTM) Dollar Retention Rate (DRR) was approximately 99%, an increase of 1 percentage point year-over-year[21,23] - TDS federal business DRR was 104% in the quarter[21] Strategic Initiatives - Launched the next-generation Skillsoft Percipio Platform with AI capabilities[21] - AI drives more than half of the design, curation, and production work for learning content[14] - Undertook a strategic review of the Global Knowledge segment, concluding that a partnership-driven model is more appropriate than continued ownership[14] Geographic Mix - Revenue geographic mix: 65% United States, 26% EMEA, 9% rest of world[27]

Financial Highlights - Planet achieved record revenue of $81.3 million in Q3'26[14] - The company's Non-GAAP Gross Margin in Q3'26 was 60%[14] - Adjusted EBITDA in Q3'26 reached $5.6 million[14] - Year-to-date Free Cash Flow amounted to $55.2 million[14] - Cash, Cash Equivalents, and Short-Term Investments totaled $677.3 million at the End of Period (EoP) Q3'26[14] Customer & Contract Wins - Planet received a $12.8 million prime contractor award from the National Geospatial-Intelligence Agency under Luno B[15] - The company was awarded a $13.2 million baseline renewal by the National Reconnaissance Office under EOCL[15] - Planet secured a $13.5 million task order from NASA under CSDA[15] - A $7.5 million renewal was awarded by the U.S Navy[15] Strategic Initiatives & Product Updates - Planet launched commercial access to Tanager-1 data, detecting over 5,500 methane plumes globally[31] - The company released a new Aircraft Detection Analytic Feed, automating daily detection of aircraft globally[36, 42] - Planet is expanding its next-generation tasking fleet with the successful launch of additional Pelican satellites[41] Revenue Breakdown - In Q3'26, 34% of revenue came from North America, 16% from Asia Pacific & Japan, 43% from Europe, Middle East, and Africa, and 5% from Latin America[47] - By sector, 61% of revenue was from Defense & Intelligence, 23% from Civil Government, and 18% from Commercial[47]

Financial Performance & Growth - Amtech's Q4 2025 net revenue is estimated at $19.8 million[32] - Q4 2025 adjusted EBITDA is estimated at $2.6 million, representing 13% of revenue[32] - The company's cash balance is estimated at $17.9 million, a $2.3 million increase from the prior quarter[32] - Fiscal year 2025 net revenue is estimated at $79.4 million[32] - Fiscal year 2025 adjusted EBITDA is estimated at $5.4 million[32] - The cash balance increased by $6.8 million from the prior year[32] Business Strategy & Market Focus - Thermal Processing Solutions segment is experiencing 5X annual growth in AI-related revenue and 60% sequential growth[17] - AI-related revenue constitutes 25% of the segment's Q3 revenue[19] - The company has implemented combined annualized savings of $13 million, reducing the breakeven point from approximately $120 million to $75 million[13] - Amtech is focused on enabling AI semiconductor device packaging and advanced substrate fabrication[3] - The company is leveraging CMP Foundry Service to grow its Chemical Consumables business[22]

Strategy and Vision - Exelixis aims to become a top 5 solid tumor oncology company by building next-generation oncology franchises across products, modalities, and tumors[8, 12] - The company plans to maintain focus on solid tumors and select modalities to maximize R&D productivity and build product, modality, and tumor franchises[13] - Exelixis anticipates sustained revenue growth through 2031 and beyond by establishing, expanding, and entrenching leadership in key tumors[5, 13] Financial Performance and Growth - Net product revenues are projected to grow from $1.63 billion in FY 2023 to approximately $2.10-$2.15 billion in FY 2025[9] - The 3L+ mCRC market is approaching $1.5 billion in 2026, representing a significant opportunity for zanzalintinib[102] - The CRC market is expected to grow from approximately $3.4 billion in 2024 to $7 billion in 2035, with a compound annual growth rate (CAGR) of 6.6%[123] Pipeline Development and Clinical Trials - Zanzalintinib's phase 3 trial (STELLAR-303) met its primary endpoint, supporting its first NDA filing[9] - Multiple zanzalintinib pivotal trials have been initiated or are planned, including two phase 3 studies in RCC in collaboration with Merck[5, 9] - STELLAR-303 trial data showed median OS of 10.9 months for Zanzalintinib + Atezolizumab arm vs 9.4 months for Regorafenib arm, with HR of 0.80 (95% CI, 0.69–0.93); P=0.0045[93] Key Product Candidates and Franchises - The company is focusing on RCC, neuroendocrine, and CRC franchises as core to its portfolio strategy[24] - XB628, a novel NKG2A x PD-L1 bispecific antibody, is in Phase 1 clinical trials with potential in IO sensitive and insensitive tumors[10, 65] - XL557, an oral SSTR2 agonist, has the potential to broadly displace SSAs in NET, with branded SSAs generating approximately $1.1 billion in U.S sales in 2024[10, 140]

Company Overview and Strategy - Azenta is uniquely positioned for strong top-line growth, margin expansion, and inorganic growth opportunities[15] - The company estimates a current serviceable addressable market (SAM) of approximately $6 billion across SMS and Multiomics[18] - Azenta's FY25 revenue was $594 million, with approximately 55% recurring revenue and 3% organic year-over-year growth[26] Sample Management Solutions (SMS) - SMS FY'25 revenue was approximately $325 million, with approximately 50% recurring revenue[85] - The SMS business has experienced a 15%+ CAGR in sample storage growth from FY'15 to FY'25[85] - The company estimates SMS has approximately 11% market share of a $3 billion serviceable addressable market[18, 88] Multiomics (GENEWIZ) - Multiomics (GENEWIZ) FY'25 revenue was approximately $269 million, with over 70% of revenue from returning customers[132] - The company estimates Multiomics has approximately 9% market share of a $3 billion serviceable addressable market[18, 137] - GENEWIZ has sequenced 15 petabytes (PB) of data and synthesized 425 million nucleotides[128] Financial Targets and Capital Allocation - The company is targeting cumulative free cash flow generation of $200 million - $250 million from FY2026 to FY2028[172] - Azenta has a $250 million share repurchase authorization[61] - The company is introducing 2028 organic financial targets including $700 million - $750 million in revenue, 6% - 8% CAGR, 70% recurring revenue, $120 million - $150 million adjusted EBITDA, and 18% - 20% adjusted EBITDA margin[186]

Investor Day December 10, 2025 Forward-looking Statements This presentation and statements by our management may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that include, without limitation, statements regarding our strategic initiatives, priorities, plans and vision; our acquisition of Sandy Spring Bancorp, Inc. ("Sandy Spring") and expectations with regard to the benefits of the Sandy Spring a ...

NASDAQ: DAKT DYNAMIC MESSAGE SIGNS Fiscal Second Quarter 2026 Results Call December 10, 2025 CONTROL SYSTEMS SAFE HARBOR STATEMENT Forward-Looking Statements: In addition to statements of historical fact, this presentation contains forward-looking statements within the meaning of the federal securities laws and is intended to receive the protections of such laws. All statements, other than historical facts, included or incorporated in this release could be deemed forward-looking statements, particularly sta ...

Business Strategy and Portfolio Repositioning - Vermilion Energy is focused on growing excess free cash flow (EFCF) by allocating capital to global gas assets, with approximately 85% of the 2026-2030 exploration & development (E&D) capital expenditures planned for these assets[6] - The company is repositioning its portfolio towards global gas assets, expecting a greater than 40% increase in production (mboe/d) and a greater than 30% decrease in cost structure and capex/flowing boe from 2024 to 2026e[44] - Vermilion aims to increase production per share by approximately 40% over five years, driven by an 8-10% annual production per share growth rate[50] Asset Performance and Outlook - The company anticipates cumulative EFCF of approximately $1.7 billion over the next five years, with annual capital expenditures between $600-630 million[50] - Vermilion's European gas assets are expected to grow organically by approximately 5,000 boe/d from 2026 to 2030, offsetting a decline of approximately 2,000 boe/d in Ireland[124] - The Montney asset is projected to reach a target production rate of 28,000 boe/d in 2028, transitioning to EFCF generation with approximately 8 wells per year to maintain production[156, 158] Financial Position and Capital Allocation - Vermilion plans a quarterly dividend of $0.135/share in 2026[8] - The company is committed to reducing net debt to FFO ratio to less than 10x, allocating 60% of EFCF to debt repayment[233, 239] - Vermilion has $11 billion of undrawn credit capacity on its revolving credit facility[205]